The Global Kidney Function Tests Market size is expected to reach $1.4 billion by 2027, rising at a market growth of 7.6% CAGR during the forecast period. There are various categories of kidney function tests or renal tests such as concentration and dilution tests, clearance tests (gives an evaluation of the filtration rate of the glomeruli, the principal filtering structures of the kidneys, and complete renal blood flow), visual and physical assessment of the urine, and identification of the concentration of various substances in the urine, mainly sodium, glucose, phosphate, potassium, and amino acids to assist in identifying possible non-function of the particular kidney functions commonly involved with their reabsorption.
The growth of the market would be boosted by many factors including high investments by the leading market players, a growing number of R&D activities, high occurrences of kidney diseases, and an increasing number of supportive government initiatives. Kidney function tests refer to simple laboratory tests which are utilized for evaluating and identifying functions of the kidney. The demand for kidney tests has been fueled by the growing cases of Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) owing to the increasing occurrences of diabetes and hypertension.
COVID 19 Impact
As per the study conducted by the National Kidney Foundation, people who needed hospitalization due to the COVID-19 are at a considerable risk of getting AKI. The study revealed that COVID-19 patients were twice vulnerable to develop AKI in comparison to non-COVID-19 patients. Health regulatory bodies suggested that COVID-19 patients who had an AKI should get regular testing as their chances of developing CKD are more as compared to others. These aspects are likely to open growth avenues for the global kidney function tests market during the forecast period.
Based on Product, the market is segmented into Clearance Test, Blood Tests, Urine Tests, Dilution & Concentration Tests, and Others. The clearance tests segment obtained a substantial revenue share of the global kidney function tests market in 2020 and would emerge as the dominating segment during the forecast period. Clearance tests are considered as the gold standard for observation and assessment of glomerular filtration rate.
End Use Outlook
Based on End Use, the market is segmented into Hospitals, Diagnostic Laboratories, Research Laboratories and Institutes and others. The diagnostic laboratories segment would garner a higher market share during the forecast years as these labs are affordable, can perform many tests, and offer precise results. The research laboratories and institutes segment would record the highest growth rate throughout the forecast period due to the growing number of R&D activities in regions like North America and Europe.
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. On the basis of region, North America appeared as the dominating region in the global kidney function tests in 2020 by obtaining the maximum revenue share of the market. The region would maintain a similar trend even during the forecast period. This is credited to the developed healthcare framework, growing awareness about CKD, and the supportive reimbursement policies and government initiatives.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens AG, Randox Laboratories Limited, Quest Diagnostics, Incorporated, Laboratory Corporation of America holdings, Sysmex Corporation, ACON Laboratories, Inc., and Nova Biomedical Corporation.
Strategies deployed in Kidney Function Tests Market
Mar-2021: Roche signed a merger agreement with GenMark Diagnostics. Under this agreement, GenMark’s syndromic panel testing portfolio would support Roche’s existing molecular diagnostics portfolio and the Roche global network would help in expanding the reach for GenMark’s products.
Nov-2020: Quest Diagnostics came into partnership with two hospital health systems. This partnership aims to improve the quality and value of diagnostic services to patients and their doctors. Under this partnership, Quest would offer laboratory management services for Montefiore Nyack Hospital & its renal physician practice Highland Medical Rockland Renal Associates in Rockland County New York and also include the daily management of the hospital laboratories, esoteric reference testing and laboratory supply chain management.
Apr-2020: Nova Biomedical announced the addition of PT/INR testing to its Allegro capillary blood analyzer for point-of-care testing in primary care settings. This update enables the company to supervise patient coagulation therapy along with the testing for glycemic control, anaemia, kidney function, gout, and cardiac risk with a full lipids panel.
Oct-2019: LabCorp teamed up with HealthEC and the New Jersey Primary Care Association (NJPCA). Together, these entities would develop a database and information exchange platform that support participating NJPCA health centres. This project would assist NJPCA members to gain value-based care goals by offering combined lab and clinical data in a better accessible, comprehensive and secure manner, with the aim of enhancing the results for patients with chronic conditions like diabetes and chronic kidney disease.
Jul-2019: LabCorp expanded its Pixel by LabCorp platform. This latest offering enables users to buy testing online, visit a convenient LabCorp patient service centre (PSC) for sample collection by a LabCorp phlebotomist, and get confidential results via a safe online portal.
Oct-2018: Siemens Healthineers collaborated with Israeli start-up, Healthy.io. Together, the companies enable patients to test their urine at home by utilizing a smartphone camera, which can scan a dipstick and then sends the results to their doctor. The collaboration expanded the companies’ capabilities to enhance the patient experience by conducting testing in their home.
Feb-2018: Randox Laboratories partnered with Qnostics, a leading provider of Quality Control solutions for molecular infectious disease testing. This partnership aimed to offer Randox Laboratories access to the Qnostics molecular line of products for sales & distribution purposes that supports the prevailing Randox Laboratories portfolio.
Dec-2017: Quest Diagnostics acquired Shiel Medical Laboratory business from Fresenius Medical Care, the premier healthcare company. Through this acquisition, Quest’s clinical laboratory in Teterboro, NJ would provide services that were earlier offered by Shiel in the New York-New Jersey metropolitan area.
Jun-2017: Nova Biomedical received the CE market for its Allegro analyzer, a capillary blood analyzer for point-of-care testing in primary care settings. The Allegro and it’s StatStrip A companion meter offers 14 tests to supervise glycemic control, evaluate cardiac risk with a full lipids panel, and evaluate kidney function.
May-2017: Sysmex Corporation introduced the semi-automated urine chemistry analyzer UC-1000. It is a product specifically in the field of urine qualitative analysis with its specific reagents, the MEDITAPE UC-10S and MEDITAPE UC-12S urine chemistry test papers, in the global markets. This product is built on a business partnership with EIKEN CHEMICAL LTD.
Scope of the Study
Market Segments covered in the Report:
• Clearance Test
• Blood Tests
• Urine Tests
• Dilution & Concentration Tests,
By End Use
• Diagnostic Laboratories
• Research Laboratories and Institutes
• North America
o Rest of North America
o Rest of Europe
• Asia Pacific
o South Korea
o Rest of Asia Pacific
o Saudi Arabia
o South Africa
o Rest of LAMEA
• Abbott Laboratories
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Siemens AG
• Randox Laboratories Limited
• Quest Diagnostics, Incorporated
• Laboratory Corporation of America holdings
• Sysmex Corporation
• ACON Laboratories, Inc.
• Nova Biomedical Corporation
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Our reports have been used by over 10K customers, including:
The in-vitro diagnostics market in Middle East and Africa is expected to grow from US$ 2,675.1 million in 2019 to US$ 3,454.0 million by 2027; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027. Aging population is vastly vulnerable to viral infections as well as chronic conditions. Diabetes in adults generates higher risk of functional...
Saudi Arabia In Vitro Diagnostics (IVD) Market, Forecast by Segments, Applications, End User, Company Analysis In-vitro diagnostics (IVD) plays a significant role in the Saudi Arabia healthcare system by providing accurate diagnosis and prognosis, thus enabling improved monitoring and treatment. Saudi...
The in-vitro diagnostics market in Europe is expected to grow from US$ 15,973.0 million in 2019 to US$ 22,221.8 million by 2027; it is estimated to grow at a CAGR of 4.2% from 2020 to 2027. The in-vitro diagnostics market has accounted for a significant market share in the healthcare industry during the COVID-19 pandemic. The market growth...
The in-vitro diagnostics market in Asia Pacific is expected to grow from US$ 13,729.8 million in 2019 to US$ 20,401.5 million by 2027; it is estimated to grow at a CAGR of 5.1% from 2020 to 2027. Incidence of chronic diseases such as cancers, chronic respiratory diseases, diabetes, and heart disease is growing due to biological risk factors,...
The in-vitro diagnostics market in North America is expected to grow from US$ 26,981.2 million in 2019 to US$ 38,759.6 million by 2027; it is estimated to grow at a CAGR of 4.7% from 2020 to 2027. Aging population is vastly vulnerable to viral infections as well as chronic conditions. For instance, according to the research conducted by American...
The in-vitro diagnostics market in South and Central America is expected to grow from US$ 4,387.7 million in 2019 to US$ 5,820.0 million by 2027; it is estimated to grow at a CAGR of 3.6% from 2020 to 2027. Automation deals with the utilization of various intelligent systems with an aim to perform any operation with minimal human intervention....
Reproductive Hormones and Proteins Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) Summary Reproductive Hormones and Proteins Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative...
The GCC in-vitro diagnostic devices market reached a value of US$ 1,233 Million in 2020. In-vitro diagnostics (IVD) refer to the clinical tests conducted on different bodily samples, such as urine, tissue and blood, to detect diseases and infections. These tests are also employed to monitor the health conditions of...
China In-Vitro Diagnostics (IVD) market is predicted to exceed US$ 21 Billion by 2027. China is a large and fast-growing in vitro diagnostics (IVD) market - in fact, only second to the United States in terms of value. Historically, large multinational companies have dominated IVD market in China; today, domestic companies such as Shanghai...
The United States In Vitro Diagnostics (IVD) market is predicted to reach nearly US$ 37 Billion by 2026. In-vitro Diagnostics (IVD) serves a key role in the healthcare value chain by significantly influencing the quality of health outcomes, patient treatment, care and downstream resource requirements. With an aging population, technological...
In Vitro Diagnostics
Cervical Cancer Screening Coverage
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.